Erytech Pharma S.A.: ERYTECH Provides Business and Financial

ERYTECH Provides Business and Financial Update for the First Quarter of 2023 Combination with Pherecydes, intending to create a global leader in extended phage therapies to target antimicrobial

Related Keywords

Paris , France General , France , Cambridge , Cambridgeshire , United Kingdom , Luxembourg , United States , French , Erytech Adss , Eric Soyer , Gil Beyen , Pharma Bio , Mathilde Bohin Louis Victor Delouvrier , Nicolas Merigeau , Enregistrement Universel , Company Securities , Euronext , Akkadian Partners Fund , Exchange Commission , Company Annual Report On Form , Financial Update , First Quarterof , Chief Executive Officer , General Assembly Meeting , June For , Akkadian Partners , Although Akkadian , Financial Highlights , Second Quarter , First Half , Third Quarter , Nasdaq Global Select Market , Next Biotech , Nasdaq Capital , Nasdaq Capital Market , French Autorit , Des March , Registration Document , Annual Report , Gefallene Big Techs , Erytech , Dharma , Rovides , Business , Financial , Update , First , Quarter , 023 ,